Bard
This article was originally published in The Gray Sheet
Executive Summary
Programmable pain pump development effort is abandoned, resulting in a Q4 write-off of $3-$6 mil. Bard has no plans to pursue any other pain management product line "at this point," Chairman and CEO Timothy Ring reported during a Jan. 28 earnings call. Revenue for 2003 totaled $1.43 bil., up 13%; net income of $168.5 mil., up 8.7%, includes a $35.5 mil. after-tax charge resulting from a brachytherapy lawsuit (1"The Gray Sheet" Jan. 5, 2004, In Brief)...
You may also be interested in...
Nelson N. Stone, MD, v. Bard
Company will file post-trial motions to set aside Manhattan district court's Dec. 19 ruling that it should pay $23 mil. for breach of contract and $35 mil. for fraud to urologists who created ProSeed, a brachytherapy seed practice management and training group. The plaintiffs claim that following its purchase of ProSeed in 1998, Bard failed "to use appropriate efforts to promote" growth of the business, "failed to pay consideration due under the agreement and induced the sale of the company by misrepresentation," Bard discloses in an 8-K SEC filing. If the verdict is not set aside or the award amount reduced, Bard plans to appeal. The firm expects the post-trial motions to be decided in Q1...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.